Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):421-425. doi: 10.1097/QAI.0000000000002136.

Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.

Author information

1
Department of Medicine and Therapeutics, University of Ghana School of Medicine and Dentistry, Korle-Bu Teaching Hospital, Accra, Ghana.
2
Department of Medicine, College of Medicine, University of Florida, Gainesville, FL.
3
Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL.
4
Department of Microbiology, School of Biomedical and Allied Health Sciences, Accra, Ghana.
5
UF Health Cancer Center, University of Florida, Gainesville, FL.

Abstract

BACKGROUND:

Incomplete hepatitis B virus (HBV) suppression during antiretroviral therapy (ART) in HIV and HBV coinfected patients is common, but underlying factors are not fully elucidated. We hypothesize that genetic factors that influence nucleoside analog pharmacokinetics will affect HBV treatment response.

METHODS:

HIV/HBV coinfected patients on tenofovir disoproxil fumarate/lamivudine (TDF/3TC)-containing ART were enrolled. Selected ABCC4 single nucleotide polymorphisms (SNPs) with known effects on nucleoside pharmacokinetics were genotyped using TaqMan assays. Relationship between ABCC4 SNPs and unsuppressed HBV DNA (HBV DNA ≥20 IU/mL) were examined.

RESULTS:

Of the 50 participants on TDF/3TC-containing ART for a median (range) of 1.5 (1-7.4) years, 20 (40%) had unsuppressed HBV DNA. Participants with unsuppressed compared with those with suppressed HBV DNA were more likely to have negative HBe antibody, lower body mass index, and lower CD4 count at enrollment. Carriers of ABCC4 rs11568695 (G3724A) variant allele were more likely than noncarriers to have unsuppressed HBV (61.1% vs. 29.0%, P = 0.038). Among 36 patients with suppressed HIV RNA (presumed good ART adherence), ABCC4 rs11568695 variant carriers were more likely than noncarriers to have unsuppressed HBV (58.8% vs. 20.0% P = 0.021). Logistic regression analysis that included genetic and nongenetic factors identified ABCC4 rs11568695 variant allele, body mass index, and male sex as predictors of unsuppressed HBV DNA.

CONCLUSIONS:

We identified a novel association between ABCC4 rs11568695 SNP and poor HBV treatment response. If confirmed in further studies, ABCC4 genotyping could be used to identify individuals who may need intensified HBV therapy.

PMID:
31335591
PMCID:
PMC6817383
[Available on 2020-12-01]
DOI:
10.1097/QAI.0000000000002136

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center